Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type
Authors:
- Elena MaccaroniEMElena Maccaroni
- Edoardo LenciELEdoardo Lenci
- Veronica AgostinelliVAVeronica Agostinelli
- Riccardo GiampieriRGRiccardo Giampieri
- Paola MazzantiPMPaola Mazzanti
- Marzia Di Pietro PaoloMPMarzia Di Pietro Paolo
- Francesca BianchiFBFrancesca Bianchi
- Cristiana BrugiatiCBCristiana Brugiati
- Laura BelvederesiLBLaura Belvederesi
- Silvia PagliarettaSPSilvia Pagliaretta
- Alessandra MandolesiAMAlessandra Mandolesi
Open Access
- 28 June 2021
- journal article
- research article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (3) , 240-248
Abstract
Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in mismatch repair (MMR) genes leading to increased risk of colon cancer as well as other cancer types. Non-small cell lung cancer (NSCLC) is not among typical Lynch syndrome-associated tumors: pembrolizumab, an immune checkpoint inhibitor, is actually approved for the treatment of NSCLC patients and represents a promising treatment option for patients with advanced metastatic MMR-deficient cancer, regardless of tumor origin. This case report describes the clinical presentation and management of a 74-year-old female with a history of rectal adenocarcinoma and ovarian cancer, who has a documented frameshift pathogenic variant in the exon 8 of MSH6 gene and an intronic variant in the BRCA2 gene (classified as a variant of uncertain significance), affected by NSCLC with brain metastases. Despite these premises, the patient was treated with pembrolizumab and she did not benefit from this kind of treatment.Keywords
This publication has 25 references indexed in Scilit:
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialThe Lancet Oncology, 2016
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAJAMA Oncology, 2016
- Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?Oncotarget, 2015
- Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer TumourPLOS ONE, 2014
- Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European expertsGut, 2013
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Lynch Syndrome GenesFamilial Cancer, 2005
- Systematic Review of Microsatellite Instability and Colorectal Cancer PrognosisJournal of Clinical Oncology, 2005
- Hereditary Colorectal CancerNew England Journal of Medicine, 2003
- A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.1998